ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Seattle Genetics, Inc." (SGEN) Report Updated: Jun 27, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Seattle Genetics, Inc." (SGEN)

Rating: Hold Volatility: Moderate
Total Grade: C Industry: Biotechnology
Competitors: FPRX,AVXL,LXRX,MNOV

Stock Analysis

Rating: Monthly View

A
B
C
D
F
June July August September October November December January February March April May

Rating: Weekly View

This Week: C down no change
Last Week: C same no change
Two Weeks Ago: C up no change
service keys

"Seattle Genetics, Inc."© quotemedia

Company Profile

Seattle Genetics, Inc., a biotechnology company, develops and commercializes antibody-based therapies for the treatment of cancer. The company is developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Its lead product, ADCETRIS (brentuximab vedotin), is an ADC that is commercially available in approximately 55 countries, including the United States, Canada, Japan, and members of the European Union for relapsed Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL) in collaboration with Takeda Pharmaceutical Company Limited. The company is evaluating ADCETRIS in approximately 30 ongoing clinical trials, including Phase III trials for post-transplant HL relapse prevention, relapsed CD30-positive cutaneous T-cell lymphoma, frontline HL in combination with chemotherapy, and frontline CD30-positive mature T-cell lymphoma in combination with chemotherapy, as well as in Phase I and II studies in various lymphoma and non-lymphoma indications. In addition, it is developing a pipeline of other clinical-stage programs, including SGN-CD19A for CD19A-positive hematologic malignancies; SGN-CD33A in CD33-positive acute myeloid leukemia; SGN-LIV1A in LIV-1-positive breast cancer; ASG-22ME for the treatment of Nectin-4-positive solid tumors; ASG-15ME for treatment of SLITRK6-positive bladder cancer; and SEA-CD40, a non-fucosylated antibody utilizing a novel immuno-oncology technology. The company has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie, Bayer, Genentech, GlaxoSmithKline, and Pfizer. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.